Get the Stockscreener App
19.88
0.30%
-0.06
After Hours:
20.00
0.12
+0.60%
Anaptysbio Inc stock is traded at $19.88, with a volume of 438.90K.
It is down -0.30% in the last 24 hours and down -41.49% over the past month.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See More
Previous Close:
$19.94
Open:
$19.64
24h Volume:
438.90K
Relative Volume:
1.17
Market Cap:
$589.80M
Revenue:
$17.16M
Net Income/Loss:
$-163.62M
P/E Ratio:
-3.8304
EPS:
-5.19
Net Cash Flow:
$-121.61M
1W Performance:
-35.45%
1M Performance:
-41.49%
6M Performance:
-25.21%
1Y Performance:
+13.41%
1-Day Range:
$19.00
$19.93
1-Week Range:
$19.00
$25.41
52-Week Range:
$13.36
$41.31
Anaptysbio Inc Stock (ANAB) Company Profile
Name
Anaptysbio Inc
Sector
Industry
Phone
858-362-6295
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-23 | Upgrade | JP Morgan | Underweight → Neutral |
| May-18-23 | Initiated | TD Cowen | Outperform |
| Jan-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-01-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Sep-13-22 | Downgrade | Truist | Buy → Hold |
| Sep-01-22 | Initiated | Raymond James | Outperform |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-22-21 | Initiated | H.C. Wainwright | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Mar-16-21 | Upgrade | Truist | Hold → Buy |
| Mar-09-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Feb-11-21 | Upgrade | JP Morgan | Underweight → Overweight |
| Oct-27-20 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-08-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-19 | Downgrade | SunTrust | Buy → Hold |
| Nov-08-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-21-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jun-21-19 | Downgrade | Stifel | Buy → Hold |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Nov-21-18 | Initiated | JP Morgan | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Apr-04-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-27-18 | Reiterated | Stifel | Buy |
| Mar-06-18 | Reiterated | Stifel | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Jan-23-18 | Reiterated | Credit Suisse | Outperform |
| Nov-15-17 | Initiated | SunTrust | Buy |
| Nov-09-17 | Initiated | Jefferies | Buy |
| Oct-11-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
View All
Anaptysbio Inc Stock (ANAB) Latest News
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Anaptys Announces Participation in November and December Investor Conferences - The Manila Times
AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.4%Should You Sell? - MarketBeat
Things To Consider Before Buying AnaptysBio Inc (NASDAQ: ANAB) - Stocks Register
AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs (NASDAQ:ANAB) - Seeking Alpha
AnaptysBio (ANAB) Shares Plunge as Eli Lilly Ends Arthritis Drug Research - GuruFocus.com
AnaptysBio (NASDAQ:ANAB) Given "Buy" Rating at HC Wainwright - MarketBeat
(ANAB) Trading Advice - Stock Traders Daily
AnaptysBio (NASDAQ:ANAB) Shares Gap DownWhat's Next? - MarketBeat
AnaptysBio (NASDAQ:ANAB) PT Raised to $33.00 - MarketBeat
AnaptysBio plunges as Eli Lilly drops co's arthritis drug from pipeline - XM
AnaptysBio stock falls as Lilly updates pipeline (ANAB:NASDAQ) - Seeking Alpha
O-I Glass Posts Downbeat Results, Joins AMD, Qorvo And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - TradingView
Assenagon Asset Management S.A. Grows Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Trading Down 6.9%Here's Why - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Receives $54.64 Consensus Price Target from Analysts - MarketBeat
AnaptysBio (NASDAQ:ANAB) PT Raised to $90.00 - Defense World
nVerses Capital LLC Buys 1,400 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Guggenheim reiterates buy rating on AnaptysBio stock, sees favorable risk/reward ahead of December readout - Investing.com Canada
A Glimpse Into The Expert Outlook On AnaptysBio Through 6 Analysts - Benzinga
AnaptysBio (NASDAQ:ANAB) PT Raised to $90.00 at Guggenheim - MarketBeat
(ANAB) On The My Stocks Page - Stock Traders Daily
AnaptysBio (NASDAQ:ANAB) Shares Down 4.9%Here's Why - MarketBeat
Piper Sandler reiterates stock target, overweight on AnaptysBio post-UEGW By Investing.com - Investing.com Canada
AnaptysBio (NASDAQ:ANAB) Trading 6.5% HigherStill a Buy? - MarketBeat
Antibody Library Technology Market Report to 2032 -AnaptysBio Inc, MorphoSys AG, XOMA Corporation, Abzena Plc, AvantGen – IndiaPolitics.com - IndiaPolitics.com
RCM Technologies, Inc. (NASDAQ:RCMT) Shares Sold by Squarepoint Ops LLC - Defense World
Objective long/short (ANAB) Report - Stock Traders Daily
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Millennium Management LLC - MarketBeat
Dimensional Fund Advisors LP Has $8.42 Million Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Point72 Asset Management L.P. Decreases Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Down 3.2%Should You Sell? - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Down 3.2% – Time to Sell? - Defense World
AnaptysBio shares hold as Piper Sandler keeps Overweight rating By Investing.com - Investing.com Canada
Susquehanna Fundamental Investments LLC Has $1.81 Million Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Anaptysbio BTLA agonist reduces atopic dermatitis inflammation - BioWorld Online
Frazier Life Sciences Management L.P. Has $54.27 Million Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Acquired by Ensign Peak Advisors Inc - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Receives $51.10 Consensus Target Price from Analysts - MarketBeat
Wedbush Reaffirms Outperform Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
What Analysts Are Saying About AnaptysBio Stock - Benzinga
AnaptysBio Insiders Selling US$3.6m In Stock Relieved As Market Cap Slides To US$1.1b - Simply Wall St
Alpha DNA Investment Management LLC Takes Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Alpha DNA Investment Management LLC Invests $399,000 in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio chief medical officer sells shares worth over $58,000 By Investing.com - Investing.com Australia
AnaptysBio chief medical officer sells shares worth over $58,000 - Investing.com
Daily Progress: Adaptive Biotechnologies Corp (ADPT) Drop -8.39, Closing at 4.26 - The Dwinnex
Mount Yale Investment Advisors LLC Reduces Stake in ServiceNow, Inc. (NYSE:NOW) - Defense World
Applied Dna Sciences Inc (APDN) Stock: A Year of Market Fluctuations - The InvestChronicle
The ADPT Stock Puzzle: Unraveling Adaptive Biotechnologies Corp’s Fluctuating Performance - The InvestChronicle
APi Group Co. (NYSE:APG) Shares Sold by Progeny 3 Inc. - MarketBeat
Anaptysbio Inc Stock (ANAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anaptysbio Inc Stock (ANAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lizzul Paul F. | Chief Medical Officer |
Sep 23 '24 |
Sale |
38.67 |
1,500 |
58,005 |
15,398 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):